Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London close: Shares end near session high

Thu, 29th Oct 2009 16:23

London's top stocks closed near its session high on news that the US economy grew faster than expected in the third quarter.Traders loved news that the US economy grew 3.5% annually in the last quarter, more than expected and the fastest rate of increase in two years.Part-nationalised bank Lloyds Banking has confirmed it is contemplating digging an escape tunnel from the government's asset protection scheme.Lloyds said it is in advanced discussions with UK authorities regarding alternatives to entering the state insurance scheme for toxic debt. The lender is considering raising cash via an underwritten rights issue and debt swap. The shares have advanced strongly on the news, dragging fellow part-nationalised lender Royal Bank of Scotland with them, while Barclays was also wanted.Asia-focused bank Standard Chartered also cheered after it said its markets in Asia, Africa and the Middle East are pulling out of the recession quicker than many markets in the West. The group, which notched up record income and profits in the first half of the year, said it continued to make 'good progress' in the third quarter.Royal Dutch Shell remained in the doghouse. In a week in which long time rival BP topped market expectations with its third quarter results, the Anglo-Dutch oil giant's third quarter earnings (on a current cost of supplies (CCS) basis) of $3bn, down from $10.9bn a year ago, failed to enthuse the market.The figures were broadly in line with expectations but upstream earnings disappointed. BG Group, which announced third quarter results yesterday, joins Shell on the slide, as does sector peer Cairn Energy. Production at Cairn's Indian operations continued to rise in the third quarter while the average realised price per barrel of oil equivalent was $51.48.AstraZeneca's third quarter earnings beat market forecasts with a 27% hike in profit at constant exchange rates (CER), prompting the Anglo-Swedish drug giant to lift full-year targets. But the excitement soon petered out and the shares fell.Life assurance group Standard Life saw strong growth in assets in the third quarter as the markets continued their recovery. Assets under management rose by £15.3bn in the third quarter to £136.9bn. Third party assets under management jumped to a record £54.1bn from £47.3bn at the end of June.Elsewhere in the sector, Prudential was better after some positive comment in the papers following yesterday's results. Sales fell 9% during the third quarter. Aviva and Legal & General are also higher.Shares in Kazakhmys recovered from a poor start. The Kazakh miner said it is on track to hit full year targets, even though maintenance work could hit Q4 output. Higher metal prices also had Xstrata, Fresnillo, Anglo American and Antofagasta ahead.Among the mid-caps, CSR posted a fall in profits but said it was seeing strong levels of business now. A change at the top at defence technology firm Qinetiq had been warmly received by the City. Graham Love is being replaced as chief executive officer at Qinetiq by the former chief of banknote printer De La Rue, Leo Quinn.Cash-strapped Yellow Pages directory publisher Yell Group has again extended the deadline for its refinancing. The company, which is looking to restructure £3.8bn of debt, extended the deadline for the third time this week after last night's cut-off passed without success.National Express fell back after calling off talks with suitor Stagecoach. It will now focus on completing an equity fundraising by the end of this year. Stagecoach said it was disappointed.Fellow rail and bus group Arriva said it has continued to trade in line with expectations since August 27 with strong growth in bus operations and a continued good performance from trains.Elsewhere in the sector, Go Ahead said it had seen growth slightly ahead of expectations in its bus and aviation operations over the first quarter and that rail operations were continuing to trade in line with forecasts.The ascent of Evolution continued, after the investment management firm said it expects to beat full year profit forecasts. Sector peer Henderson Group was cold shouldered, however, despite assets under management increasing by 9% to £57.7bn in the third quarter.FTSE 100 - RisersRoyal Bank of Scotland Group (RBS) 43.37p +9.52%Lloyds Banking Group (LLOY) 86.00p +7.50%Xstrata (XTA) 947.00p +7.37%Fresnillo (FRES) 802.00p +6.65%Kazakhmys (KAZ) 1,186.00p +6.56%Anglo American (AAL) 2,300.00p +5.60%SEGRO (SGRO) 363.30p +5.40%Prudential (PRU) 577.50p +4.90%Vedanta Resources (VED) 2,218.00p +4.57%Eurasian Natural Resources (ENRC) 889.00p +4.47%FTSE 100 - FallersRoyal Dutch Shell 'B' (RDSB) 1,813.00p -3.02%Royal Dutch Shell 'A' (RDSA) 1,856.00p -2.88%AstraZeneca (AZN) 2,752.00p -1.33%BAE Systems (BA.) 315.20p -1.22%British American Tobacco (BATS) 1,939.00p -0.92%Shire Plc (SHP) 1,024.00p -0.68%Smith & Nephew (SN.) 543.00p -0.55%Severn Trent (SVT) 954.50p -0.52%Alliance Trust (ATST) 308.60p -0.48%Rentokil Initial (RTO) 105.10p -0.47%
More News
7 Aug 2019 11:47

Evgen Pharma Gets European Patent Covering Composition Of SFX-01

(Alliance News) - Evgen Pharma PLC on Wednesday said it has secured further intellectual property rights in Europe for SFX-01.The drug development company, focused on breast cancer and said

Read more
5 Aug 2019 11:45

Evgen Pharma To Collaborate With King's College And British Heart

(Alliance News) - Evgen Pharma PLC said Monday that it backs the new research collaboration between King's College London and the British Heart Foundation.The collaboration is how - - a

Read more
18 Jul 2019 13:00

Evgen Pharma Outlook Confident As Progresses Programmes Development

(Alliance News) - Evgen Pharma PLC on Thursday expressed confidence for the year ahead as it continued to progress on the development of its clinical programmes.Ahead of its annual general

Read more
13 Jun 2019 12:21

Evgen Pharma Annual Loss Fractionally Wider On Small Expense Rise

(Alliance News) - Evgen Pharma PLC on Thursday said its loss marginally widened in its most recent financial year due to slightly higher expenses as drug development continues.Clinical drug

Read more
13 Jun 2019 09:03

Evgen Pharma losses edge wider on higher costs

(Sharecast News) - Evgen Pharma on Thursday reported a slightly widened annual loss due to a cost increase, with its results in line with expectations as its drugs remain in the development stage.

Read more
17 Apr 2019 13:17

Evgen Pharma Raises GBP5 Million Via Share Placing (ALLISS)

LONDON (Alliance News) - Evgen Pharma PLC said Wednesday it raised GBP5.0 million via issue of shares in an oversubscribed placing.The clinical stage drug development company issued 13.1 at

Read more
25 Mar 2019 10:23

Good Headline Results From Evgen Pharma Breast Cancer Study Of SFX-01

LONDON (Alliance News) - Evgen Pharma PLC on Monday announced positive headline results from its phase two Stem trial of SFX-01 in advanced breast cancer.Shares in the clinical-stage drug -

Read more
18 Mar 2019 11:10

Evgen Pharma Expects STEM Trial Read-Out Next Week

LONDON (Alliance News) - Evgen Pharma PLC on Monday said it expects the final read-out of its STEM trial in metastatic breast cancer to be announced early next week, in line with its guidance of

Read more
5 Mar 2019 11:35

Study Of Evgen Pharma's SFX-01 Multiple Sclerosis Drug Shows Promise

LONDON (Alliance News) - Clinical stage drug developer Evgen Pharma PLC on Tuesday said a study has been published showing that its lead product, SFX-01, reduces residual disability in a model of

Read more
5 Feb 2019 09:18

Evgen Pharma Finishes Patient Recruitment For Stroke Treatment Trial

LONDON (Alliance News) - Evgen Pharma PLC on Tuesday said it has completed patient recruitment in its SAS phase II trial for proposed treatment SFX-01.SFX-01 is a planned treatment for a an

Read more
12 Dec 2018 11:11

Evgen Pharma Interim Loss Widens As It Progresses New Drug Trials

LONDON (Alliance News) - Evgen Pharma PLC on Wednesday said its interim loss widened slightly for its most recent half as it focuses on advancing trials.For the six month to September 30, a

Read more
12 Dec 2018 10:10

Evgen Pharma's loss widens amid excitement over cancer treatment

(Sharecast News) - Evgen Pharma's shares stumbled on Wednesday after its interim loss before tax expanded, though the company was "delighted" by progress in treatment developments.

Read more
23 Oct 2018 12:55

David And Monique Newlands Build 5% Stake In Evgen Pharma (ALLISS)

LONDON (Alliance News) - Evgen Pharma PLC said Tuesday that David and Monique Newlands now own 5.06% stake in the company.The Newlands' holding before the transaction, if any, was not

Read more
18 Oct 2018 10:26

Evgen Pharma Raises GBP750,000 Via Share Placing (ALLISS)

LONDON (Alliance News) - Evgen Pharma PLC said Thursday it raised GBP750,000 via share placing.The company issued 5.6 million shares at 13.5p. Shares in the drug development company were at

Read more
11 Sep 2018 12:51

Tueday broker round-up

(Sharecast News) - JD Wetherspoons: Berenberg upgrades to buy with a target price of 1,450p.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.